Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE Study.
Alexey RuzinOlivier BarraudLi YuBruno FrançoisMiguel Sánchez-GarciaPhilippe EggimannPierre-François DequinPierre-François LaterreVincent HuberlantLucia ViñaThierry BoulainCedric BretonniereJérôme PuginJosé TrenadoAna Catalina Hernandez PadillaJulie VignaudDrieke VandammeHerman GoossensChristine LammensS Omar AliKathryn ShoemakerPin RenSusan ColbertTerramika BellamyBret R SellmanMichael McCarthyHasan S JafriMark T Essernull nullPublished in: Journal of clinical microbiology (2022)
We investigated the performance of the Xpert methicillin-resistant Staphylococcus aureus (MRSA)/S. aureus skin and soft tissue (SSTI) quantitative PCR (qPCR) assay in SAATELLITE, a multicenter, double-blind, phase 2 study of suvratoxumab, a monoclonal antibody (MAb) targeting S. aureus alpha-toxin, for reducing the incidence of S. aureus pneumonia. The assay was used to detect methicillin-susceptible S. aureus (MSSA) and MRSA in lower respiratory tract (LRT) samples from mechanically ventilated patients. LRT culture results were compared with S. aureus protein A ( spa ) gene cycle threshold ( C T ) values. Receiver operating characteristic (ROC) and Youden index were used to determine the C T cutoff for best separation of culture-S. aureus-negative and S. aureus-positive patients. Of 720 screened subjects, 299 (41.5%) were S. aureus positive by qPCR, of whom 209 had culture data: 162 (77.5%) were S. aureus positive and 47 (22.5%) were S. aureus negative. Culture results were negatively affected by antibiotic use and cross-laboratory variability. An inverse linear correlation was observed between C T values and quantitative S. aureus culture results. A spa C T value of 29 (≈2 × 10 3 CFU/mL) served as the best cutoff for separation between culture-negative and culture-positive samples. The associated area under the ROC curve was 83.8% (95% confidence interval [CI], 78 to 90%). Suvratoxumab provided greater reduction in S. aureus pneumonia or death than placebo in subjects with low S. aureus load ( C T ≥ 29; relative risk reduction [RRR], 50.0%; 90% CI, 2.7 to 74.4%) versus the total study population (RRR, 25.2%; 90% CI, -4.3 to 46.4%). The qPCR assay was easy to perform, sensitive, and standardized and provided better sensitivity than conventional culture for S. aureus detection. Quantitative PCR C T output correlated with suvratoxumab efficacy in reducing S. aureus pneumonia incidence or death in S. aureus-colonized, mechanically ventilated patients.
Keyphrases
- methicillin resistant staphylococcus aureus
- end stage renal disease
- ejection fraction
- newly diagnosed
- staphylococcus aureus
- chronic kidney disease
- double blind
- intensive care unit
- clinical trial
- risk factors
- high throughput
- gene expression
- respiratory tract
- dna methylation
- mass spectrometry
- drug delivery
- peritoneal dialysis
- patient reported
- machine learning
- placebo controlled
- genome wide
- phase ii
- sensitive detection
- atomic force microscopy
- binding protein
- single cell
- cancer therapy
- liquid chromatography
- wound healing
- cross sectional
- single molecule
- open label
- electronic health record
- phase iii